Dr. Rowe has well over a decade of research experience spanning from pre-clinical to late phase drug development programs, primarily in respiratory (and cardiovascular) medicine. He has been directly responsible for medical strategy and lifecycle management of several Chronic Obstructive Pulmonary Disease (COPD), asthma, and cardiovascular medicines. Dr. Rowe has been successfully involved in achieving New Drug Application (NDA) approvals for first in therapeutic class respiratory products and also has led various clinical development global projects from phase II through phase IV clinical trials. He has authored and co-authored several publications in respiratory medicine (COPD-focused, and is a frequent lecturer and speaker at professional society meetings, and educational forums. Dr. Rowe holds degrees from Harvard University and the University of Rochester School of Medicine, and certifications from the London School of Economics and Villanova University.
Dr. Rowe is an active member of several national and international societies and he recently served as Vice Chair of the Drug, Device, Discovery, and Development Committee of the American Thoracic Society (ATS). He has a primary interest in promoting international medical research collaboration and innovation across government, academia, and industry.
In his current role, Dr. Rowe is responsible for building and leading a Global Medical Affairs team and strategy within the respiratory space for several novel compounds in mid and late stage development, in various therapeutic indications.
Sam Rasty is an associate professor of Clinical & Administrative Sciences at the California Northstate University College of Pharmacy (CNUCOP). He received his Doctor of Pharmacy degree from the Ferris State University. After graduation, Dr. Rasty completed a Cardiovascular Pharmacotherapy Fellowship at Henry Ford Hospital in Detroit, MI. Dr. Rasty was the clinical coordinator in cardiac and medical intensive care unit at Advocate Christ Medical Center and since 2004 has held various academic, and pharmaceutical industry positions in Medical and Regulatory affairs prior to joining CNUCOP. Most recently Dr. Rasty completed a Master’s degree in public health with a focus in epidemiology. Dr. Rasty’s research primarily focuses on patient health outcomes in cardiovascular pharmacotherapy.
Dr. Kanmaz has served on the faculty at St. John’s University, College of Pharmacy and Health Sciences since 1996 with an interim three-year appointment as an HIV Clinical Science Manager at Abbott Laboratories. During her time at Abbott, she served as the HIV clinical expert for the 5 boroughs of New York, attended national and international HIV/AIDS conferences, developed and presented post-conference educational slide decks, collaborated on phase IV investigator-initiated studies, developed key opinion leaders, participated in regional advisory board meetings, and supported the sales and marketing teams.
She is currently the Assistant Dean for Experiential Pharmacy Education and Associate Clinical Professor in the Department of Clinical Health Professions. She has received several grants directed toward the care of patients with HIV/AIDS and disadvantaged persons in high poverty situations. She is certified as an American Academy of HIV Medicine HIV Expert as well as a certified Smoking Cessation Counselor. Dr. Kanmaz is also an active member of several committees within the American Association of Colleges of Pharmacy10, Experiential Education Special Interest Group.
Dr. Mehul Patel has more than 11 years of experience within the pharmaceutical and medical communications industry. He is currently employed as a Director of Medical Affairs at Allergan, providing medical leadership for the cardiovascular, metabolic and psychiatry portfolio. Responsibilities include developing aligned global medical strategic plans and providing medical input into tactical activities within these therapeutic areas. He as has authored multiple publications and has conducted numerous live CME and non CME lectures. In addition to his current role, Mehul gained his medical affairs/communications experience at PDL BioPharma and at Embryon Inc.. In addition, he spent five years working as a clinical program lead at Biogen Idec where his responsibilities included constructing strategic clinical development plans for drug candidates in the cardiovascular, CNS and immunology therapeutic areas.
Dr. Patel received his doctorate in pharmacy at the Ernest Mario School of Pharmacy (Rutgers University).